Nonclinical

Current Epidemiological Data Can Help Predict Future Incidence of CCA

March 2023, Vol 4, No 1 — April 4, 2023

A recent epidemiological study showed that the incidence of cholangiocarcinoma has been increasing in the United States, and researchers sifted the data with an aim to help plan prevention and treatment strategies.

Survival Outcomes in Patients with iCCA and Solitary versus Multiple Tumors

Nonclinical, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

Researchers investigated risk factors for intrahepatic cholangiocarcinoma and the prognostic significance of tumor multiplicity identified by surgical resection.

Genetic Classification of iCCA Can Have Significant Prognostic Value

Nonclinical, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

A retrospective review was conducted using the hidden-genome classifier to quantify the genetic heterogeneity of intrahepatic cholangiocarcinoma with a view toward improved tumor classification.

Cost-Effectiveness of GemCis with or without Durvalumab in Patients with Advanced CCA

Nonclinical, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

The clinical benefit of durvalumab plus GemCis in patients with advanced cholangiocarcinoma has been proved, but affordability of the regimen remains a concern. A cost analysis of this treatment regimen considers issues related to outcomes versus the financial toxicity experienced by patients.

Nonclinical

Subscribe Today!

I'd like to receive:

Stay In The Know